Taisuke Hoshi

Tsukuba, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

A Phase 1b Study of Lenvatinib plus Nivolumab in Patients with Unresectable Hepatocellular Carcinoma.

A Phase 1b Study of Lenvatinib plus Nivolumab in Patients with Unresectable Hepatocellular Carcinoma.

Journal: Liver cancer

Published: April 21, 2025

Cell-free DNA-based inference of the activities of 370 + transcription factors mirrors their activities in tumors.

Cell-free DNA-based inference of the activities of 370 + transcription factors mirrors their activities in tumors.

Journal: BMC genomics

Published: March 13, 2025

Population pharmacokinetic-pharmacodynamic modeling of serum biomarkers as predictors of tumor dynamics following lenvatinib treatment in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC).

Population pharmacokinetic-pharmacodynamic modeling of serum biomarkers as predictors of tumor dynamics following lenvatinib treatment in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC).

Journal: CPT: pharmacometrics & systems pharmacology

Published: November 28, 2023

Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades.

Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades.

Journal: Biochemical and biophysical research communications

Published: January 28, 2019

Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models.

Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models.

Journal: Cancer medicine

Published: December 11, 2017

Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus.

Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus.

Journal: Cancer science

Published: September 22, 2016

The MuSK activator agrin has a separate role essential for postnatal maintenance of neuromuscular synapses.

The MuSK activator agrin has a separate role essential for postnatal maintenance of neuromuscular synapses.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: November 05, 2014

Mesdc2 plays a key role in cell-surface expression of Lrp4 and postsynaptic specialization in myotubes.

Mesdc2 plays a key role in cell-surface expression of Lrp4 and postsynaptic specialization in myotubes.

Journal: FEBS letters

Published: July 29, 2013

Showing 1-8 of 8

Last Updated: 09/26/2026